同和药业：原料药美阿沙坦钾通过药品GMP符合性检查

Core Viewpoint - The company has successfully passed the GMP compliance inspection for its raw material drug, Azilsartan Potassium, which is expected to enhance its sales in the domestic market and establish a synchronized sales pattern in both domestic and international markets [1] Group 1 - The drug Azilsartan Potassium is indicated for the treatment of primary hypertension in adults [1] - The successful GMP compliance is a significant milestone for the company, facilitating market expansion [1]